TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06162741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Brief Mindfulness Training (PCBMT)
Description: PCBMT is a manualized intervention that is a brief adaptation of MBSR Mindfulness Based Stress Reduction (MBSR). It was developed by Dr. Scott Treatman and Dr. Dessa Bergen-Cico (Co-I). PCBMT consists of four 90-minute classes (360 total minutes of classes). Instruction encompasses sitting meditation, body scan, moving meditation, gentle yoga, and group discussion on topics such as non-judging, patience, trust, non-striving, acceptance, and letting go. In-class meditations are followed by a group process of the experience. At-home practice between sessions is encouraged and is guided by simple checklists asking students to check the meditation they practiced and write a few comments about what the experience was like.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moving Forward (MF)
Description: Moving Forward (MF) is a transdiagnostic class that seeks to build resilience and reduce emotional distress by teaching step-by-step problem-solving skills such as stop, slow down, think and act. The format that will be used as the comparison is manualized, group-delivered, primary care-based, often co-delivered by MH providers and peers, and considered a usual care practice in many VHA PCMHI programs. MF content is derived from problem solving therapy, which has clear effectiveness in reducing depression and other types of psychological distress. While the MF manual consists of four 60-minutes classes, for this study the 4 classes will be 90-minutes long to equate the length of both conditions. No new content will be added rather the additional time will be used to allow Veterans to complete worksheets in class and allow more group discussion.
Study: NCT05426837

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combatting Social Isolation
Description: A brief, computerized psychoeducational intervention designed to target ways to cope with and address loneliness and social isolation in older adults modeled after our group's previous Building Stronger Allies (BSA) intervention.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health Education Training
Description: Control condition where participants learn about healthy lifestyle behaviors.
Study: NCT06123546

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient oriented discharge summary
Description: The intervention consists of three components: the patient-oriented discharge summary (PODS), the teach-back technique and the involvement of caregivers.~The PODS will be completed with participants over the course of the hospitalisation as teaching content related to the six sections of information is delivered. Participants will take the PODS home at discharge to use it as a reference for relevant and individualized discharge information in the post-discharge period.~Healthcare providers will receive a training refresher on the teach-back technique and will be reminded to use it when they deliver discharge teaching during participants' hospital stay.~Involvement of caregivers will include early identification by the healthcare provider responsible for patient admission of a caregiver who will provide care at home, at least one teaching session during hospitalization and the review of the PODS the day of discharge.
Study: NCT06179186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.
Study: NCT05256017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acoziborole
Description: Acoziborole tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo of acoziborole tablets
Study: NCT06179186

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light
Description: The axilla will be treated with intense pulsed light, being right or left, depending upon randomization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: The axilla will be treated with diode laser, being right or left, depending upon randomization.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diode Laser
Description: The axilla will be treated with diode laser, being right or left, depending upon randomization.
Study: NCT05444361

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis
Description: Cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be treated on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). For active probes, the gas will be deployed to the tip where a drop in temperature to approximately -70°C will result in cryoneurolysis.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham cryoneurolysis of the 2nd-6th thoracic intercostal nerves will be applied on the ipsilateral surgical side (bilaterally for bilateral surgical procedures): for each nerve the cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods (Epimed) or 1 cycle of 5.5 minutes \[all but 4 participants: 064-067\] or 3 minutes \[only 4 participants 064-067; change based on new laboratory data, then changed back based on inadequate freeze\] of argon and 30 seconds of helium (Varian). However, for sham probes, the gas is not deployed to the tip and therefore there is no drop in temperature resulting in cryoneurolysis.
Study: NCT06649214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine-samidorphan；
Description: orally once daily, tablet, 10mg/10mg、15mg/10mg or 20mg/10mg，duration of 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: orally once daily, tablet, 10mg、15mg or 20mg，duration of 24 weeks.
Study: NCT06650501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Patients will be assigned to change to dabigatran at the monograph approved dose for their indication, bleeding risk, and renal function.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: edoxaban
Description: Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Patients will continue taking their currently prescribed apixaban, edoxaban, or rivaroxaban
Study: NCT06650631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Heatwraps
Description: To treat the painful knee joint in patients with osteoarthritis without acute flares or inflammation. The investigational device will be used in accordance with the Instructions for Use.
Study: NCT06651424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Combination of Lactobacillus probiotics (no comercial)
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will consume 1 capsule per day in one of the main meals without any restriction in the diet or in their life habits
Study: NCT06650033

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive radiotherapy +/- margin reduction
Description: Radiotherapy using adaptive technology to recontour and re-plan daily as required. Reductions in the PTV margin will also be introduced in the second phase of this study.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Image guided radiotherapy
Description: Standard radiation treatment used in the department of radiation oncology for cancer in pelvic area
Study: NCT04894045

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized management
Description: Intraoperative MAP will be maintained at least at the mean nighttime MAP (assessed using preoperative automated blood pressure monitoring). If the mean nighttime MAP is below 65 mmHg, intraoperative MAP will be maintained at least at 65 mmHg.
Study: NCT05438199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toilet seat that measures waste output
Description: Participants will use a toilet that includes a apparatus designed to measure waste output.
Study: NCT05312801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAFF CAR-T
Description: Autologous CAR-T cell therapy expressing the BAFF-ligand.
Study: NCT05227937

Intervention type: DRUG
Intervention: Amikacin
Description: patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
Study: NCT06054750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 800 mg ropivacaine in continuous infusion adductor canal block (400 mL total volume)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 400 mL normal saline in continuous infusion adductor canal block (400 mL total volume)
Study: NCT06452524

Intervention type: DEVICE
Intervention: axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)
Description: Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.

Intervention type: DEVICE
Intervention: axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)
Description: Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.

Intervention type: DEVICE
Intervention: axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)
Description: Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.

Intervention type: DEVICE
Intervention: axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT)
Description: Non-cycloplegic and cycloplegic refraction, best corrected visual acuity (BCVA), axial length (AU) and anterior chamber depth (ACD), optical coherence tomography (OCT) macular and OCT subfoveal choroidal measurements were performed in all cases.
Study: NCT05354375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at PSMA.
Study: NCT06650293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D supplementation as vitamin D, 2 drops i.e., 800 IU daily for 5 days.
Study: NCT04992559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Toripalimab
Description: Toripalimab consolidation therapy after radiotherapy or chemoradiotherapy, 240mg IV, every 3 weeks, until progressive disease (PD), start new anti-cancer therapy, intolerable toxicity, withdraw informed consent or other conditions that require study treatment discontinuation. Toripalimab will be given at a maximum of 12 months.
Study: NCT05815771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro fragmented adipose tissue mixed with bone marrow stem cells
Description: mixture of stem cells
Study: NCT05136729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Natural Posture Exercise training
Description: SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Natural Posture Exercise training
Description: SNPE training will be provided face-to-face or online by certified instructors. The SNPE exercise training involves the use of special belts to align and stabilize posture and joints. Up to 4 belts can be used, placed around the hips, around the thighs, below the knees, and above the ankles. Myofascial release is part of the training, which is self-performed with SNPE equipment.
Study: NCT05815771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro fragmented adipose tissue mixed with bone marrow stem cells
Description: mixture of stem cells

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Micro fragmented adipose tissue mixed with bone marrow stem cells
Description: mixture of stem cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow stem cells aspirate
Description: stem cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow stem cells aspirate
Description: stem cells

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone Marrow stem cells aspirate
Description: stem cells
Study: NCT05149976

Intervention type: DIAGNOSTIC_TEST
Intervention: Voice recording before and after dietary intake
Description: * A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Voice recording before and after dietary intake
Description: * A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test.

Intervention type: DIAGNOSTIC_TEST
Intervention: Voice recording before and after dietary intake
Description: * A person who is scheduled to undergo a VFSS test, and his/her voice is recorded before and after eating for the VFSS test~* For general subjects, only voice recordings were conducted before and after food/water intake without a VFSS test.
Study: NCT06642376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: Breathing Exercise Application Group
Description: The Effect of Breathing Exercise Applied to Intensive Care Nurses on Fatigue and Perceived Stress
Study: NCT05937581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration
Study: NCT05598229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tik Tok
Description: Encourage and do not restrict watching Tik Tok
Study: NCT06122324

Intervention type: DRUG
Intervention: Lidocaine Hydrochloride
Description: Patients in Group 1 will receive 40 mg of lidocaine HCl solution 5 minutes before endotracheal intubation.
Study: NCT05937581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration
Study: NCT05301205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral gabapentin
Description: will be received oral gabapentin capsule 2 HOURS pre-operatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral gabapentin
Description: will be received oral gabapentin capsule 2 HOURS pre-operatively.
Study: NCT05680766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular endurance training
Description: Based on the results of a maximal effort test, investigators will provide a personalised training program. Results of a submaximal effort test after 6 weeks, will allow for adaptation of the training program for the remaining training period.
Study: NCT05937581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL040
Description: IV Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v NaCI, IV Administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v NaCI, IV Administration
Study: NCT05395754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App Intervention
Description: Use of the PCheck app, an app encouraging STI prevention behaviors.
Study: NCT04879823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV Dexamethasone Sodium Phosphate will be prescribed orally at a dose of 0.5mg/kg with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The Dexamethasone will be mixed by the parents with 5mL of pre-packaged cherry syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen will be prescribed at 10 mg/kg to be taken every 6 hours for the first three post-operative days. After the first three days, the subject should take the ibuprofen every 6 hours as needed for pain control. The daily dose of ibuprofen is not to exceed 1200mg or more than 4 individual doses. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be prescribed at 15mg/kg to be taken every 4 hours for the first three days, except when sleeping. After the first three days, the subject should take the acetaminophen every 4 hours as needed for pain control. The daily dose of acetaminophen is not to exceed 5 doses in 24 hours. It will be prescribed in liquid suspension form for ease of use in pediatric populations. Subjects or parents will purchase this medication and dosage will be given to subjects in easy-to-understand language.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An equal volume of water will be prescribed to patients (0.5mg/kg) with a max dose of 20mg to be taken the morning of days 2, 4, and 6 post-operatively. The placebo (water) will be mixed by the parents with 5mL of pre-packaged cherry syrup.
Study: NCT06457256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS-A-FUERTE
Description: CLS-A-FUERTE Intervention Description: The CLS-A-FUERTE program is a school clinician training and psychosocial intervention program designed to improve attention and behavior in Mexican school-aged youth (grades 1-5). Participating school clinicians are supported by a clinical research team of trainers who co-leads weekly training/consultation meetings and observes each intervention component (i.e., 6 weekly parent and student skills groups, as well as classroom management in the form of a Daily Report Card) in-vivo via videoconferencing.
Study: NCT06650605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 123I-ATT001
Description: 123I-ATT001
Study: NCT06651177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide is available in single dose vials at six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg/0.5 mL. A study MC will administer the once-weekly SQ dose of tirzepatide. Consistent with tirzepatide's prescribing guidelines, participants will be initiated at a once-weekly SQ dose of 2.5 mg/week with a dose increase to 5mg/week at week 5. Consistent with tirzepatide's prescribing information, once the participant has received 5 mg/week for 4 weeks they are eligible for a dose increase if needed

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matched placebo (containing saline) will be created for use in the trial. A study MC will administer the once-weekly SQ dose of saline. The process for deciding on dose increases will be the same for placebo and tirzepatide.
Study: NCT04708327

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STAT-205
Description: naltrexone hydrochloride capsules 4.5 mg each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT-205
Description: naltrexone hydrochloride capsules 4.5 mg each
Study: NCT06649760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain and loss framed mobile text messages
Description: To assess the effect of message framing on enhancing oral health practices in a group of refugees

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gain and loss framed mobile text messages
Description: To assess the effect of message framing on enhancing oral health practices in a group of refugees